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A B S T R A C T
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe but treatable disease that is commonly
underdiagnosed. Computed tomography lung subtraction iodine mapping (CT-LSIM) in addition to standard CT
pulmonary angiography (CTPA) may improve the evaluation of suspected chronic pulmonary embolism and
improve the diagnostic pick up rate. We aim to recruit 100 patients suspected of having CTEPH and perform CT-
LSIM scans in addition to the current gold standard test of nuclear medicine test (lung single photon emission
computed tomography (SPECT) imaging) as a pilot study which will contribute to and inform the deﬁnitive trial.
The diagnostic accuracy of CT-LSIM and lung SPECT will be compared. The primary outcome of the full deﬁ-
nitive study is non-inferiority of CT-LSIM versus lung SPECT imaging.
1. Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a
treatable, life-threatening disease that occurs in up to 4% of patients
following acute pulmonary embolism (PE) [1]. The disease is char-
acterised by remodelling of the pulmonary arteries due to poor clear-
ance of clot. Prognosis is very poor without treatment, and pulmonary
endarterectomy (PEA) is well established as the deﬁnitive and poten-
tially curative treatment method for CTEPH.
The European Society of Cardiology recommends ventilation/per-
fusion single photon emission tomography (V/Q SPECT) as the ﬁrst
line-screening test for patients with CTEPH. The perfusion image in-
volves injection of 99mTc labelled macroaggregated human albumin,
exposing the patient to ionizing radiation and the study acquisition
time is 30–40min.
Evaluation of the pulmonary arterial tree by computed tomography
pulmonary angiography (CTPA) and lung perfusion is required to de-
termine the appropriate treatment strategy in chronic thromboembolic
disease (CTED). Recently, there has been much interest in the appli-
cation of lung perfused blood volume images using dual-energy CT
(DECT) to assess lung perfusion [2,3]. However, DECT is not widely
available in hospitals across the UK and V/Q SPECT remains the re-
ference standard. The rationale, methodology and design of the IodiNe
Subtraction mapping in the diagnosis of Pulmonary chronIc thRom-
boEmbolic disease (INSPIRE) study are summarised in this paper.
1.1. Rationale of the INSPIRE study
Computed tomography lung subtraction iodine mapping (CT-LSIM)
and accompanying software is now available in routine clinical practice
(Sure subtractionTM, Toshiba Medical Systems; FDA report K130960).
CT-LSIM images are created using on a non-rigid registration of a low
dose unenhanced thoracic CT to a CTPA, with both examinations per-
formed during the same sitting in less than 10min total scanning time.
Subtraction of the non-contrast CT from the contrast-enhanced CTPA
produces the CT-LSIM. CT-LSIM simultaneously provide high-spatial-
resolution images of the pulmonary arterial tree and parenchymal
anatomy in combination with functional examination of lung perfusion.
Magnetic resonance imaging (MRI) is an alternative approach with
the advantage of the lack of ionizing radiation and can produce lung
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perfusion maps with good diagnostic accuracy for CTED [5]. MRI is
relatively limited in comparison to CT in terms of availability and the
lack of ability to provide an out of hours service in some centres. Re-
cently, it has been shown that Gadolinium is deposited in the basal
ganglia, the clinical signiﬁcance of the retained gadolinium in the
brain, if any, remains unknown [4]. Further research is ongoing.
A recent meta-analysis and systematic review, highlights the diag-
nostic potential of CT in both screening and for surgical and interven-
tional operability [6].
Replacement of CT for V/Q SPECT in the setting of screening for
CTED would lead to a £325 saving per patient. The diagnosed annual
incidence of CTEPH is approximately 700 cases in the UK, projected to
rise to about 1000 in 2025. Estimated pick up rate of perfusion defects
in patients with suspected CTED is 59% at a specialist centre (pick up
rates are likely to be much lower at non-specialist centres). An esti-
mated 1186 patients are screened at specialist centres, if these patients
were screened using CT instead of SPECT, cost savings would be made
in the UK based on current estimates.
In patients found to have CTED on lung SPECT, CTPA is also re-
quired to characterise the extent of pulmonary arterial clot for surgical
planning which adds further cost. The total saving of a pathway using
CTPA with iodine subtraction mapping for screening and surgical
planning is potentially signiﬁcant.
1.1.1. Aims and objectives of the INSPIRE study
The main objective of the INSPIRE study is to assess the diagnostic
performance of CT-LSIM for evaluation of pulmonary perfusion in pa-
tients with known or suspected CTEPH. The primary hypothesis is that
CT-LSIM is more sensitive than V/Q SPECT and CTPA in the assessment
of CTED in patients with known or suspected CTEPH. We also hy-
pothesize that the diagnostic performance of the experienced observers
will be better than the less experienced and that the number of alternate
diagnoses made on CT-LSIM will be higher and more accurate than lung
SPECT imaging.
2. Materials and methods
2.1. Design and setting
The INSPIRE study is a single centre cross sectional observational
diagnostic study comparing the diagnostic accuracy for new test CT-
LSIM with nuclear medicine SPECT. The setting of the study is a tertiary
referral centre for pulmonary hypertension. Patients will be recruited
during their admission to the Sheﬃeld Pulmonary Vascular Disease
unit. CT scans will be performed in the Radiology Department at the
Royal Hallamshire Hospital. Patients will be identiﬁed by the
Pulmonary Hypertension team from their clinic visit as suspected CTED
or CTEPH. Patients will be sent information sheets and written in-
formed consent and those will be obtained from all the patients.
Consent will be taken by a research team member on admission for
diagnostic visit that includes CT scanning. The study is registered on
clinicaltrials.gov (NCT03806907).
2.2. Eligibility
Patients are eligible to be included in the INSPIRE study if they are
suspected to have CTED or CTEPH and require a SPECT and CTPA.
Patients will be excluded if they are less than 18 years old, unable to
provide informed consent, have signiﬁcant renal dysfunction
(GFR<30ml/min), have a history of hypersensitivity to contrast ma-
terial or pregnant.
2.3. Imaging protocol
Images will be evaluated for objective and subjective image quality.
No additional contrast will be used as compared to standard clinical
practice as patients will only undergo one CTPA scan. The CT protocol
of this study has been carefully designed to have a radiation dose
identical or even lower than standard CT protocols for PE detection.
2.4. CTPA and LSIM acquisition
CT examinations will be performed on a 320 detector-row CT
system (Aquilion ONE/ViSION edition; Toshiba Medical Systems,
Otawara, Japan). After non-contrast CT is performed, contrast material
will be injected for 25 s via an antecubital vein using a weight-adapted
injection protocol. Scanning will be initiated 3 and 14 s after the at-
tenuation in the region of interest (ROI) placed in the pulmonary artery
reached the threshold of +100 HU under the single breath hold. CT
images will be reconstructed using adaptive iterative dose reduction.
The image data sets shall be analyzed with the algorithm on the
post-processing software attached to Aquilion ONE/Vision Edition
(SURESubtraction Lung). Based on a non-rigid registration followed by
subtraction of the non-contrast images from the contrast-enhanced
images (CTPA images), a colour map is produced showing the iodine
distribution in the lung parenchyma.
2.5. Nuclear medicine SPECT acquisition
SPECT imaging will be performed on a General Electric Inﬁnia
SPECT system using a low energy general purpose collimator. 100 MBq
99mTc MAA will be administered through a direct intravenous injec-
tion with a needle of 21G or larger. The image acquisition parameters
are: acquisition matrix 128x128, 60 projections per detector and 7 s per
projection. Images will be acquired prone with the patient's arms ex-
tended above their heads, where possible.
Fig. 1 illustrates coronal (1a) and axial (1b) CT-LSIM showing a
classical triangular segmental perfusion defect (red arrows). Fig. 2 il-
lustrates coronal (2a) and axial (2b) SPECT lung perfusion scintigraphy
images showing the same segmental perfusion defect. Note the sharper
delineation of the perfusion defect on CT.
2.6. Radiation dose
The typical eﬀective dose for lung perfusion scintigraphy, was
2.04–2.86mSv determined by the normalized coeﬃcient. A study of 50
patients [7] using the same scanner used in our hospital found a median
dose length product of 171mGy cm, corresponding to an eﬀective ra-
diation dose of approximately 2.90mSv, using a conversion factor of
0.017 mSv/mGycm for chest CT. Hence the advantages described above
can be achieved with a similar radiation dose to a nuclear medicine
lung scintigraphy scan and patients who require both CTPA and SPECT
have a lower total dose.
Fig. 1. Coronal (1a) and axial (1b) CT-LSIM showing a classical triangular
segmental perfusion defect (red arrows). (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the Web version of this
article.)
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2.7. Image analyses
All images will be anonymised and given unique study identiﬁers.
Analysis will be performed using a commercially available diagnostic
workstation (OsiriX).
2.8. Radiological evaluation
CT-LSIM and CTPA images shall be respectively evaluated by three
observers, two consultant Radiologists and a Radiology resident who
were blinded to the clinical data (observer 1: a thoracic radiologist with
8 years of specialist experience, observer 2: a thoracic radiologist with 7
years of experience and observer 3 a Radiology resident with 4 years’
experience), following which a consensus read will be performed by
observer 1 and 2. The scores of each reader will be adopted, as they
were if scores are matched. If scores of each reader are diﬀerent, either
shall be adopted after the discussion of two readers. In addition, the 2nd
reading session of observer 1 will be performed to determine intra-
observer agreement.
LSIM images will be scored primarily as positive, negative or in-
determinate. If abnormal a severity score will be assigned. Score 1, if
normal perfusion, score 2 if mild perfusion defects (< 25%); score 2,
moderate perfusion defects (25–50%), and class 3, severe perfusion
defects (> 50%).
CTPA will be scored primarily as positive, negative or in-
determinate. In addition, the clot burden will be semi-quantitatively
scored as mild, moderate or severe, and predominantly proximal or
distal.
2.9. Sample size
This study has been powered to demonstrate non-inferiority of CT
LSIM compared to SPECT lung scintigraphy, with 90% power, assuming
a percentage success estimated from a previous study, assuming 95%
sensitivity and 95% speciﬁcity; a 10% non-inferiority margin and 11%
discordant pairs. This proportion must be bigger than the non-in-
feriority margin of 10%. With 90% power and 5% two-sided sig-
niﬁcance and estimated prevalence of 60%, 290 cases are required (116
without the disease and 174 with the disease). The pilot study we will
aim to recruit 100 cases which will contribute to the deﬁnitive trial. The
analysis of the results of the pilot study will allow a more precise es-
timate of full trial size.
We perform approximately 260 SPECT lung scintigraphy scans a
year for suspected CTED/CTEPH and we expect to recruit 50% of these
patients based on studies on CTED/CTEPH patients previously done at
our institution. Hence would expect to complete the pilot study re-
cruitment (n= 100) in 1 year and the full study in approximately 3
years depending on recruitment rate and sensitivity/speciﬁcity results
from the pilot study. A ﬂow chart of study design is shown in Fig. 3.
2.10. Statistical analysis
A Statistical Package for the Social Sciences Program (SPSS) version
24 for Windows (SPSS Inc. Chicago, IL) will be used for statistical
analysis. Continuous variables will be expressed as mean ± standard
deviation (SD) for parametric variables and median (interquartile
range) for non-parametric variables. Categorical data will be presented
as the number of subjects and percentage.
A Chi-squared test will be used to establish sensitivity, speciﬁcity,
positive and negative predictive values for detecting the presence and
absence of PE. The Kappa (κ) statistic will be used to determine the level
of agreement between the independent observers. The κ value will be
deﬁned as follows: values < 0 indicated lack of agreement; 0–0.20,
slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate
agreement; 0.61–0.80, substantial agreement; 0.81–1, almost perfect
agreement.
All statistical tests will be two sided with a p value of less than 0.05
considered to be statistically signiﬁcant.
3. Discussion
The INSPIRE study is a single centre prospective observational study
which will aim to assess the sensitivity and speciﬁcity of CT-LSIM
compared to CTPA and SPECT imaging in the diagnosis of CTEPH. It
will also assess the performance of CT-LSIM in the evaluation of lung
perfusion compared to the previous imaging modalities in CTEPH pa-
tients.
INSPIRE is the ﬁrst study to compare the speciﬁcity and sensitivity
of CT-LSIM to CTPA and SPECT imaging in the diagnosis of CTEPH. The
only other study which assessed the diagnostic performance of CT-LSIM
was conducted by Tamura et al. [7] comparing the diagnostic perfor-
mance of CT-LSIM to CTPA using SPECT as a reference standard in 50
patients with CTEPH. The authors concluded that CT-LSIM is a feasible
technique for the assessment of segmental lung perfusion in patients
with CTEPH and provides a higher diagnostic accuracy compared to
CTPA. Of note, Tamura et al. [7] only compared CT-LSIM to CTPA.
Furthermore, SPECT imaging was based on lung perfusion only with no
assessment of ventilation. The sample size is also small to draw any
generalizable conclusions which was acknowledged as a limitation of
the study. INSPIRE is the ﬁrst study to provide a head to head com-
parison of CT-LSIM with SPECT which is the current gold standard in a
large cohort of patients. The aim of the INSPIRE study is to become a
multicentre study following the initial single centre pilot phase and
recruit approximately 300 patients who are diagnosed or suspected to
have CTEPH.
Previous studies have compared dual energy CT (DECT) [8–10],
CTPA [11] and 3-D contrast enhanced lung perfusion MRI [12] to
SPECT imaging for the evaluation of segmental lung perfusion in pa-
tients with CTEPH. These studies showed superior diagnostic perfor-
mance of DECT compared with SPECT but not CTPA. However, despite
DECT proving to be superior to SPECT imaging, the latter remains the
reference standard perhaps due to the small number of patients in-
cluded in these studies and because of lack of access to DECT due to the
high cost.
CTPA, although oﬀers an improved better spatial resolution and
additional morphological information compared to nuclear medicine
scintigraphy, it has lower sensitivity in detecting peripherally located
perfusion defects compared to SPECT. Thus, SPECT imaging remains
superior to CTPA despite the latter showing higher speciﬁcity [13].
CTEPH is a life shortening complication of acute PE which results in
the formation of intravascular scars leading to increased pulmonary
hypertension [14]. Currently, the gold standard treatment for these
lesions is PEA in patients deemed ﬁt for surgery and for proximal dis-
ease [15]. For patients who are unﬁt for surgery and for lesions which
are inaccessible surgically such as segmental and subsegmental disease,
balloon pulmonary angioplasty (BPA) has been recently introduced as a
Fig. 2. Coronal (2a) and axial (2b) SPECT lung perfusion scintigraphy images
showing the same segmental perfusion defect. Note the sharper delineation of
the perfusion defect on CT.
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treatment option [16,17]. Therefore, pre BPA planning of segmental
perfusion is essential and currently is assessed by a combination of
CTPA and SPECT. INSPIRE hypothesise that CT-LSIM has the potential
to oﬀer a more accurate visualisation and assessment of lung segmental
perfusion as pre-treatment planning tool for patients eligible for BPA.
The results of this study are important as CT-LSIM has the potential
to cut down the cost of having two investigations (CTPA and SPECT),
reduce the radiation dose by approximately 3–4 mSV and can be a one
stop investigation reducing the number of patients visits to hospital
from two to one visit.
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